secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2022-12-22T23:59:59+00:00
Accession:  0001601485-22-000073
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Angion Biomedica gets Nasdaq bid-price deficiency notice; 180 days to cure
--------------------------------------------------------------------------

- Received Nasdaq notice on Dec 15, 2022 for common stock closing below $1.00 for 30 consecutive business days.
- Has until June 13, 2023 to regain compliance with minimum $1.00 closing bid for at least 10 consecutive days.
- Company says notification will not adversely impact its ongoing strategic realignment process.
- If not compliant by deadline, may qualify for an additional 180-day period and consider a reverse stock split.
- Currently meets all other Nasdaq listing standards except the bid price requirement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148522000073/0001601485-22-000073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148522000073/angn-20221215.htm
  HTML page:      https://secwatch.observer/filing/0001601485-22-000073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer